SYPL1 and non-small cell lung carcinoma: Liposomal doxorubicin conjugated to HSP1, HSP2, and HSP4 showed significantly greater therapeutic efficacy than non-targeted liposomal drugs in NSCLC (H460 and H1993) animal models [100].